TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Clinical Trial on the Effects of Recreational Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy: The FC Prostate Study
Brief Summary: Androgen Deprivation Therapy (ADT) is standard treatment for locally advanced or advanced Prostate Cancer (PC).

The musculoskeletal toxicity associated with ADT is well established, leading to a decrease in muscle mass, increased fat percentage, weight gain, sexual dysfunction and increased risk of depression, fatigue, diabetes, cardiovascular disease and reduced quality of life.

Numerous studies have shown an association between physical activity, physical capacity and quality of life in cancer patients and recent epidemiological research suggest that regular, moderate-intensity physical activity may have a positive effect on survival in men with prostate cancer.

Within exercise physiology there is new evidence pointing to recreational soccer as a unique form of intermittent exercise that effectively stimulates aerobic and anaerobic energy delivery systems, leading to beneficial musculoskeletal, metabolic and cardiovascular adaptations of importance for health.

It is our overall hypothesis that 12 weeks of recreational soccer training 2-3 times per week will improve the health profile of PC patients receiving ADT treatment.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
B: Arm Label: Soccer Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Soccer training | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Soccer training; Assigned to Arm(s): Soccer Training
C: Arm Label: Standard PA Recommendation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telephone Implementation Intention; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Implementation Intention | Arm Label: Self-completed implementation intention; Type: EXPERIMENTAL; Interventions: Behavioral: Self-completed implementation intention | Intervention Type: BEHAVIORAL; Name: Telephone Implementation Intention; Assigned to Arm(s): Telephone Implementation Intention | Intervention Type: BEHAVIORAL; Name: Self-completed implementation intention; Assigned to Arm(s): Self-completed implementation intention
D: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Training | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): Exercise

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vilazodone in the Treatment of Social Anxiety Disorder: A Double Blind Study
Brief Summary: The purpose of this study is to determine whether Vilazodone is effective in the treatment of symptoms of Social Anxiety Disorder among adults.


Options:
A: Intervention Type: DRUG; Name: LY686017; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Arm Label: Vilazodone; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: PH94B intranasal spray; Type: EXPERIMENTAL; Interventions: Drug: PH94B intranasal spray | Arm Label: Placebo intranasal spray; Type: PLACEBO_COMPARATOR; Interventions: Drug: PH94B intranasal spray | Intervention Type: DRUG; Name: PH94B intranasal spray; Assigned to Arm(s): PH94B intranasal spray, Placebo intranasal spray
D: Intervention Type: DRUG; Name: vestipitant; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV Multicenter, Randomized, Open Label, Two-Period, Crossover Study in Patients With Cystic Fibrosis to Evaluate the Comparable Efficacy and Safety of Pulmozyme Delivered by the eRapid Nebulizer System
Brief Summary: This phase IV, multicenter, randomized, open-label, two-period crossover study will evaluate the comparable efficacy and safety of Pulmozyme (dornase alfa) delivered by the eRapid nebulizer system in patients with cystic fibrosis. Patients who have been receiving Pulmozyme once daily chronically for at least 6 months will continue to receive Pulmozyme once daily for a run-in period of 2 weeks using the Pari LC Plus nebulizer. Patients will then be randomized to receive in a crossover design Pulmozyme once daily for two treatment periods of 2 weeks each using either the Pari LC Plus or the eRapid nebulizer. Anticipated time on study treatment is 6 weeks.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: inhaled mannitol | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: inhaled mannitol; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): B
B: Arm Label: Pulmozyme; Type: EXPERIMENTAL; Interventions: Drug: Pulmozyme (dornase alfa) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pulmozyme (dornase alfa); Assigned to Arm(s): Pulmozyme | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Master Study Run-in; Type: N/A; Interventions: N/A
D: Arm Label: eRapid Nebulizer; Type: EXPERIMENTAL; Interventions: Drug: dornase alfa [Pulmozyme®] | Arm Label: Jet Nebulizer; Type: ACTIVE_COMPARATOR; Interventions: Drug: dornase alfa [Pulmozyme®] | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): eRapid Nebulizer | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): Jet Nebulizer

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV Multicenter, Randomized, Open Label, Two-Period, Crossover Study in Patients With Cystic Fibrosis to Evaluate the Comparable Efficacy and Safety of Pulmozyme Delivered by the eRapid Nebulizer System
Brief Summary: This phase IV, multicenter, randomized, open-label, two-period crossover study will evaluate the comparable efficacy and safety of Pulmozyme (dornase alfa) delivered by the eRapid nebulizer system in patients with cystic fibrosis. Patients who have been receiving Pulmozyme once daily chronically for at least 6 months will continue to receive Pulmozyme once daily for a run-in period of 2 weeks using the Pari LC Plus nebulizer. Patients will then be randomized to receive in a crossover design Pulmozyme once daily for two treatment periods of 2 weeks each using either the Pari LC Plus or the eRapid nebulizer. Anticipated time on study treatment is 6 weeks.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mannitol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dornase alpha | Arm Label: 3; Type: OTHER; Interventions: Drug: mannitol + pulmozyme | Intervention Type: DRUG; Name: mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: mannitol + pulmozyme; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dornase alpha; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): N/A
D: Arm Label: eRapid Nebulizer; Type: EXPERIMENTAL; Interventions: Drug: dornase alfa [Pulmozyme®] | Arm Label: Jet Nebulizer; Type: ACTIVE_COMPARATOR; Interventions: Drug: dornase alfa [Pulmozyme®] | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): eRapid Nebulizer | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): Jet Nebulizer

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV Multicenter, Randomized, Open Label, Two-Period, Crossover Study in Patients With Cystic Fibrosis to Evaluate the Comparable Efficacy and Safety of Pulmozyme Delivered by the eRapid Nebulizer System
Brief Summary: This phase IV, multicenter, randomized, open-label, two-period crossover study will evaluate the comparable efficacy and safety of Pulmozyme (dornase alfa) delivered by the eRapid nebulizer system in patients with cystic fibrosis. Patients who have been receiving Pulmozyme once daily chronically for at least 6 months will continue to receive Pulmozyme once daily for a run-in period of 2 weeks using the Pari LC Plus nebulizer. Patients will then be randomized to receive in a crossover design Pulmozyme once daily for two treatment periods of 2 weeks each using either the Pari LC Plus or the eRapid nebulizer. Anticipated time on study treatment is 6 weeks.


Options:
A: Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): N/A
B: Arm Label: eRapid Nebulizer; Type: EXPERIMENTAL; Interventions: Drug: dornase alfa [Pulmozyme®] | Arm Label: Jet Nebulizer; Type: ACTIVE_COMPARATOR; Interventions: Drug: dornase alfa [Pulmozyme®] | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): eRapid Nebulizer | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): Jet Nebulizer
C: Arm Label: 1; Type: OTHER; Interventions: Drug: rhDNAse, Other: Placebo | Arm Label: 2; Type: OTHER; Interventions: Drug: rhDNAse, Other: Placebo | Intervention Type: DRUG; Name: rhDNAse; Assigned to Arm(s): 1, 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mannitol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dornase alpha | Arm Label: 3; Type: OTHER; Interventions: Drug: mannitol + pulmozyme | Intervention Type: DRUG; Name: mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: mannitol + pulmozyme; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dornase alpha; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV Multicenter, Randomized, Open Label, Two-Period, Crossover Study in Patients With Cystic Fibrosis to Evaluate the Comparable Efficacy and Safety of Pulmozyme Delivered by the eRapid Nebulizer System
Brief Summary: This phase IV, multicenter, randomized, open-label, two-period crossover study will evaluate the comparable efficacy and safety of Pulmozyme (dornase alfa) delivered by the eRapid nebulizer system in patients with cystic fibrosis. Patients who have been receiving Pulmozyme once daily chronically for at least 6 months will continue to receive Pulmozyme once daily for a run-in period of 2 weeks using the Pari LC Plus nebulizer. Patients will then be randomized to receive in a crossover design Pulmozyme once daily for two treatment periods of 2 weeks each using either the Pari LC Plus or the eRapid nebulizer. Anticipated time on study treatment is 6 weeks.


Options:
A: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
B: Arm Label: eRapid Nebulizer; Type: EXPERIMENTAL; Interventions: Drug: dornase alfa [Pulmozyme®] | Arm Label: Jet Nebulizer; Type: ACTIVE_COMPARATOR; Interventions: Drug: dornase alfa [Pulmozyme®] | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): eRapid Nebulizer | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): Jet Nebulizer
C: Arm Label: Tigerase®; Type: EXPERIMENTAL; Interventions: Biological: Tigerase® | Arm Label: Pulmozyme®; Type: ACTIVE_COMPARATOR; Interventions: Biological: Pulmozyme® | Intervention Type: BIOLOGICAL; Name: Tigerase®; Assigned to Arm(s): Tigerase® | Intervention Type: BIOLOGICAL; Name: Pulmozyme®; Assigned to Arm(s): Pulmozyme®
D: Arm Label: TIS/TIP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tobramycin Inhalation Powder, Drug: Tobramycin inhalation solution | Arm Label: COLI/TIP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tobramycin Inhalation Powder, Drug: Colistimethate | Arm Label: TIP/TIP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tobramycin Inhalation Powder | Intervention Type: DRUG; Name: Tobramycin Inhalation Powder; Assigned to Arm(s): COLI/TIP, TIP/TIP, TIS/TIP | Intervention Type: DRUG; Name: Tobramycin inhalation solution; Assigned to Arm(s): TIS/TIP | Intervention Type: DRUG; Name: Colistimethate; Assigned to Arm(s): COLI/TIP

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Supervised Physical Exercise on Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus
Brief Summary: The purpose of this study is to evaluate the effect of supervised physical exercise on endothelial function and number of endothelial progenitor cells (EPCs) in patients with systemic lupus erythematosus, as well as evaluate the effect of supervised physical exercise on endothelium derived growth factor (VEGF) levels, disease activity, quality of life, fatigue, perceived exertion and cardiopulmonary exercise test variables.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Aerobic exercise group; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: Anaerobic exercise group; Type: EXPERIMENTAL; Interventions: Other: Exercise | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Aerobic exercise group, Anaerobic exercise group
B: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Healthy control; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): Exercise, Healthy control
C: Arm Label: Supervised physical exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised physical exercise | Arm Label: No supervised physical exercise; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised physical exercise; Assigned to Arm(s): Supervised physical exercise
D: Arm Label: Placebo plus SOC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Belimumab 1 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 1 mg/kg | Arm Label: Belimumab 4 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 4 mg/kg | Arm Label: Belimumab 10 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus SOC | Intervention Type: DRUG; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg plus SOC | Intervention Type: DRUG; Name: Belimumab 4 mg/kg; Assigned to Arm(s): Belimumab 4 mg/kg plus SOC | Intervention Type: DRUG; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg plus SOC

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III,Randomized,Open Label Study Comparing Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa up to 2-3 Years for ≤ 45 Year Old Pre-menopausal Hormone Receptor-positive Breast Cancer
Brief Summary: The present study is a randomized open-label -phase III study that aims to compare the efficacy and safety of the adjuvant chemotherapy with simultaneous or sequential application of Zoladex up to 2-3 years for ≤ 45 year old premenopausal hormone receptor-positive breast cancer.


Options:
A: Arm Label: Standard Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide | Arm Label: Chemotherapy Plus Goserelin; Type: EXPERIMENTAL; Interventions: Drug: cyclophosphamide, Drug: goserelin acetate | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Chemotherapy Plus Goserelin, Standard Chemotherapy | Intervention Type: DRUG; Name: goserelin acetate; Assigned to Arm(s): Chemotherapy Plus Goserelin
B: Arm Label: T+OFS; Type: ACTIVE_COMPARATOR; Interventions: Drug: tamoxifen, Drug: triptorelin | Arm Label: E+OFS; Type: EXPERIMENTAL; Interventions: Drug: exemestane, Drug: triptorelin | Intervention Type: DRUG; Name: exemestane; Assigned to Arm(s): E+OFS | Intervention Type: DRUG; Name: tamoxifen; Assigned to Arm(s): T+OFS | Intervention Type: DRUG; Name: triptorelin; Assigned to Arm(s): E+OFS, T+OFS
C: Arm Label: Zoladex combined with chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Zoladex | Arm Label: Zoladex after chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zoladex | Intervention Type: DRUG; Name: Zoladex; Assigned to Arm(s): Zoladex after chemotherapy, Zoladex combined with chemotherapy
D: Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: epirubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: triptorelin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase Ⅲ Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Arterial Hypertension Patients
Brief Summary: Previous studies suggest that combinations of existing therapies may be effective for pulmonary arterial hypertension (PAH). However, all of these studies are sequential combination therapy, for example, by adding sildenafil to previously prescribed bosentan. This kind of therapy model is not enough for PAH patients, especially those with New York Heart Association (NYHA) class Ⅲ and Ⅳ. In this randomized, multicenter study, the investigators evaluate the safety and efficacy of combining inhaled iloprost, a prostacyclin analog, with the endothelin receptor antagonist bosentan in treatment naive patients with PAH by comparing with bosentan monotherapy. Efficacy endpoints include change from baseline in 6-min-walk distance (6-MWD), modified (NYHA) functional class, hemodynamic parameters, and time to clinical worsening.


Options:
A: Arm Label: ACT-293987 (NS-304) and matching placebo; Type: EXPERIMENTAL; Interventions: Device: ACT-293987 (NS-304) | Intervention Type: DEVICE; Name: ACT-293987 (NS-304); Assigned to Arm(s): ACT-293987 (NS-304) and matching placebo
B: Arm Label: Combination therapy; Type: EXPERIMENTAL; Interventions: Drug: Iloprost, Drug: Bosentan | Arm Label: monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Iloprost; Assigned to Arm(s): Combination therapy | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Combination therapy, monotherapy
C: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral treprostinil (UT-15C) sustained release tablets | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oral treprostinil (UT-15C) sustained release tablets; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: UT-15C SR; Type: EXPERIMENTAL; Interventions: Drug: UT-15C SR | Intervention Type: DRUG; Name: UT-15C SR; Assigned to Arm(s): UT-15C SR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase Ⅲ Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Arterial Hypertension Patients
Brief Summary: Previous studies suggest that combinations of existing therapies may be effective for pulmonary arterial hypertension (PAH). However, all of these studies are sequential combination therapy, for example, by adding sildenafil to previously prescribed bosentan. This kind of therapy model is not enough for PAH patients, especially those with New York Heart Association (NYHA) class Ⅲ and Ⅳ. In this randomized, multicenter study, the investigators evaluate the safety and efficacy of combining inhaled iloprost, a prostacyclin analog, with the endothelin receptor antagonist bosentan in treatment naive patients with PAH by comparing with bosentan monotherapy. Efficacy endpoints include change from baseline in 6-min-walk distance (6-MWD), modified (NYHA) functional class, hemodynamic parameters, and time to clinical worsening.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tezosentan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tezosentan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: Combination therapy; Type: EXPERIMENTAL; Interventions: Drug: Iloprost, Drug: Bosentan | Arm Label: monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Iloprost; Assigned to Arm(s): Combination therapy | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Combination therapy, monotherapy
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bosentan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C